PER-025-10已完成未知
RANDOMIZED, DOUBLE-BLIND, TRIPLE-DUMMY TRIAL TO COMPARE THE EFFICACY OF OTAMIXABAN WITH UNFRACTIONATED HEPARIN + EPTIFIBATIDE, IN PATIENTS WITH UNSTABLE ANGINA/NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION SCHEDULED TO UNDERGO AN EARLY INVASIVE STRATEGY
sanofi-aventis Recherche & Development,0 个研究点目标入组 50 人开始时间: 2010年5月18日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients with Acute Coronary Syndrome without STE segment elevation
- •Patients in whom coronary angiography is planned (followed by PCI, when indicated) as soon as possible (after at least 2 hours of treatment with the study medication) and within 36 hours (no later than Day 3 , if justified)
- •Informed consent obtained in writing
排除标准
- •High probability of not being available for follow-up on Day 180
- •Age <18 years (or legal age in the country)
- •Pregnancy, demonstrated by a positive urine pregnancy test, performed before randomization (applicable only to women with the potential to conceive, that is, premenopausal or postmenopausal women for <2 years)
- •Treatment with other investigating agents (including placebo) or devices within 30 days prior to randomization, or planned use of investigating agents or devices during the study
- •Breastfeeding
- •A revascularization procedure has already been performed for the qualifying event.
- •Acute MI with ST segment elevation
- •Patients who have received a curative dose of an anticoagulant treatment (including UFH, LMWH, or bivalirudin) for more than 24 hours before randomization.
- •Inability to suspend the current anticoagulation to make the transition to Research Products according to the time specified for the transition.
- •Patients who cannot be treated with acetylsalicylic acid and clopidogrel (or with any other oral antiplatelet agent) according to their local product information.
- •Patients who cannot be treated with eptifibatide according to the national product information (when available). In countries where eptifibatide is not approved, the reference product information to be considered will be the European product information or the product information in the USA (see Appendix H and Appendix I).
- •Patients who cannot be treated with unfractionated heparin according to national product information
- •Allergy to otamixaban
研究者
相似试验
进行中（未招募）
不适用
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO TEST THE EFFICACY, SAFETY AND TOLERABILITY OF LITHIUM IN MULTIPLE SYSTEM ATROPHY - Lithium in MSAEUCTR2009-016377-15-ITIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II
进行中（未招募）
1 期
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF 6 MONTHS VERSUS 12 MONTHS CLOPIDOGREL THERAPY AFTER IMPLANTATION OF A DRUG-ELUTING STENTPatients with established coronary artery disease on chronic clopidogrel therapy at 6 months after coronary drug eluting stent implantation.MedDRA version: 17.0Level: PTClassification code 10011078Term: Coronary artery diseaseSystem Organ Class: 10007541 - Cardiac disordersEUCTR2007-006263-68-DEDeutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen4,000
进行中（未招募）
1 期
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF 6 MONTHS VERSUS 12 MONTHS CLOPIDOGREL THERAPY AFTER IMPLANTATION OF A DRUG-ELUTING STENT SAFETY AND EFFICACY OF SIX MONTHS DUAL ANTIPLATELET THERAPY AFTER DRUG-ELUTING STENTING – ISAR-SAFE - ISAR-SAFEPatients with established coronary artery disease on chronic clopidogrel therapy at 6 months after coronary drug eluting stent implantation.MedDRA version: 14.0Level: PTClassification code 10011078Term: Coronary artery diseaseSystem Organ Class: 10007541 - Cardiac disordersEUCTR2007-006263-68-ATDeutsches Herzzentrum Muenchen6,000
进行中（未招募）
1 期
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF 6 MONTHS VERSUS 12 MONTHS CLOPIDOGREL THERAPY AFTER IMPLANTATION OF A DRUG-ELUTING STENT SAFETY AND EFFICACY OF SIX MONTHS DUAL ANTIPLATELET THERAPY AFTER DRUG-ELUTING STENTING – ISAR-SAFE - ISAR-SAFEPatients with established coronary artery disease on chronic clopidogrel therapy at 6 months after coronary drug eluting stent implantation.MedDRA version: 14.1Level: PTClassification code 10011078Term: Coronary artery diseaseSystem Organ Class: 10007541 - Cardiac disordersEUCTR2007-006263-68-DKDeutsches Herzzentrum Muenchen6,000
尚未招募
不适用
Bridging Trial of Bivalent Killed Oral Cholera Vaccine in EthiopiaCholeraPACTR201202000354245International Vaccine Institute216